ONTX Onconova Therapeutics Inc

Price (delayed)

$5.09

Market cap

$80.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.8

Enterprise value

$32.32M

Highlights
The equity has surged by 74% year-on-year
The EPS has soared by 50% YoY and by 14% from the previous quarter
The company's revenue has shrunk by 89% YoY
The gross profit has dropped by 89% year-on-year

Key stats

What are the main financial stats of ONTX
Market
Shares outstanding
15.78M
Market cap
$80.33M
Enterprise value
$32.32M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.16
Price to sales (P/S)
316.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
137.53
Earnings
Revenue
$235,000
EBIT
-$24.78M
EBITDA
-$24.76M
Free cash flow
-$23.28M
Per share
EPS
-$1.8
Free cash flow per share
-$1.59
Book value per share
$2.36
Revenue per share
$0.02
TBVPS
$3.34
Balance sheet
Total assets
$48.85M
Total liabilities
$11.7M
Debt
$0
Equity
$37.15M
Working capital
$41.32M
Liquidity
Debt to equity
0
Current ratio
6.64
Quick ratio
6.56
Net debt/EBITDA
1.94
Margins
EBITDA margin
-10,537.4%
Gross margin
100%
Net margin
-10,544.7%
Operating margin
-10,198.3%
Efficiency
Return on assets
-81.1%
Return on equity
-139.3%
Return on invested capital
N/A
Return on capital employed
-59.7%
Return on sales
-10,543%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ONTX stock price

How has the Onconova Therapeutics stock price performed over time
Intraday
-5.91%
1 week
-0.59%
1 month
-28.31%
1 year
-70.23%
YTD
-27.18%
QTD
-26.55%

Financial performance

How have Onconova Therapeutics's revenue and profit performed over time
Revenue
$235,000
Gross profit
$235,000
Operating income
-$23.97M
Net income
-$24.78M
Gross margin
100%
Net margin
-10,544.7%
The company's revenue has shrunk by 89% YoY
The gross profit has dropped by 89% year-on-year
Onconova Therapeutics's net income has decreased by 30% YoY
The company's operating income fell by 22% YoY but it rose by 4.1% QoQ

Growth

What is Onconova Therapeutics's growth rate over time

Valuation

What is Onconova Therapeutics stock price valuation
P/E
N/A
P/B
2.16
P/S
316.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
137.53
The EPS has soared by 50% YoY and by 14% from the previous quarter
The equity has surged by 74% year-on-year
The stock's price to book (P/B) is 72% less than its last 4 quarters average of 7.6
The price to sales (P/S) is 174% higher than the 5-year quarterly average of 115.4 but 37% lower than the last 4 quarters average of 502.1
The company's revenue has shrunk by 89% YoY

Efficiency

How efficient is Onconova Therapeutics business performance
ONTX's return on equity has surged by 59% year-on-year and by 23% since the previous quarter
ONTX's return on assets is up by 25% year-on-year and by 15% since the previous quarter
The ROS has grown by 3.2% from the previous quarter

Dividends

What is ONTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ONTX.

Financial health

How did Onconova Therapeutics financials performed over time
ONTX's total assets has surged by 144% since the previous quarter and by 52% year-on-year
The quick ratio has increased by 46% year-on-year
The debt is 100% less than the equity
The equity has surged by 74% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.